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TABLE 8. Multivariate Cox regression, disease-free survival adjusted
for clinical stage
HR P
Age 1.00 (0.99–1.02) .761
Male gender 1.14 (0.81–1.60) .465
Performance status>0 1.95 (1.49–2.57) <.001
Poor differentiation 1.42 (1.09–1.86) .009
Squamous cell type 1.06 (0.78–1.46) .693
Induction 1.22 (0.91–1.62) .178
En bloc resection 0.62 (0.45–0.87) .006
Advanced clinical stage 2.75 (1.71–4.41) <.001
HR, Hazard ratio.
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Sesophagectomy (39% en bloc vs 29% transhiatal), statistical
significancewas not achieved. The authors subsequently pub-
lisheda subgroupanalysis and showed that the long-termben-
efit of an en bloc resection could be attributed to the subgroup
of patients with lower third carcinoma of the esophagus, in
whom the estimated 5-year survival benefit of an en bloc re-
section was 14%.23 The authors also showed that for patients
with limited nodal disease (1–8 positive lymph nodes) DFS
was significantly improved after en bloc resection.24 In the
absence of anothermore definitive randomized trial, this con-
troversy is likely to continue.
Limitations
Despite our best efforts to collect the data prospectively,
this study remains a retrospective review and thus subject to
all the inherent limitations of such reviews. For example,
unintended biases such as selection or referral bias cannot
be reasonably excluded. This study also extended over
a 22-year period, during which there has been evolution in
staging techniques and multimodality treatment of esopha-
geal cancer. More recently, there has been an obvious shift
toward increasing use of PET scanning in preoperative stag-
ing and of preoperative chemotherapy or chemoradiation.
CONCLUSIONS
Our results suggest that, for patients with good perfor-
mance status and clinically staged as stage II or greater,
en bloc resection is associated with a higher probability of
FFR and a significant improvement in DFS. Patients with
clinical stage I may be adequately treated by a standard re-
section technique.
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Dr David Rice (Houston, Tex). I have nothing to disclose.
Congratulations on an excellent presentation, Paul, and thank
you very much for giving me the slides and the manuscript well
in advance of the meeting.
Dr Lee and his colleagues from Cornell present an impressive
series of 500 patients who underwent an esophagectomy forgery c May 2011
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Sesophageal cancer over a 22-year period. The majority of patients
underwent surgery alone, but a third also received induction che-
motherapy. Two thirds had an en bloc esophagectomy with either
a 2-field or 3-field lymphadenectomy. Of the remaining one third,
the majority of these had a transhiatal resection. Consistent with
most other large Western series, adenocarcinoma predominated
and over 80% of cases were clinical stage II or higher. I applaud
the authors on such a low mortality rate.
There is much controversy regarding the oncologic adequacy of
transhiatal esophagectomy. Proponents argue that no randomized
trial has shown significant inferiority in terms of survival, and cer-
tainly pulmonary morbidity is lessened. What is beyond doubt,
however, is that transhiatal esophagectomy compromises on the
extent of mediastinal node dissection that is achievable. Whether
or not this influences local recurrence and survival is the subject
of this manuscript. In multivariate analysis, Lee and colleagues
found that en bloc esophagectomy was an independent predictor
of longer disease-free survival. The survival benefit of en bloc
esophagectomy compared with the standard approach was espe-
cially marked for patients with stage III and stage IV tumors. Nev-
ertheless, there was only a marginal difference in the proportion of
isolated local recurrences that favored the en bloc approach by
only 3 percentage points.
My first question to Dr Lee and his colleagues is whether factors
other than a less extensive nodal dissection could have resulted in
the worse disease-free survival seen with a standard esophagec-
tomy. Is it possible that patients who did not undergo en bloc
esophagectomy had factors that would have predicted poor out-
come anyway and that we may be dealing with selection bias? Fur-
thermore, was there any difference in cancer-specific death
between the standard and the en bloc groups?
DrLee.Thank you, Dr Rice, for those very thoughtful questions
and your comments.
To answer your question, we did look at the performance status
between the en bloc group and the non–en bloc group and there
was no difference in terms of performance status. Each group
was pretty much evenly split with PS0 and PS1. It is true that
the en bloc group had younger patients. The median age was 63
as opposed to 68. And when we did look at comorbidities, there
seemed to be a high incidence of severe pulmonary artery disease
in the transhiatal group. Nonetheless, we did look at the cancer-
specific survival and we excluded those patients who died from
other causes in the analysis. We found that for stage I there was
no difference; however, for stage II, III, and IV, there was a signif-
icant difference in improved cancer-specific survival in the en bloc
group in contrast to the non–en bloc group.
Dr Rice.My second question pertains to the extent of lympha-
denectomy required. As you know, the trial by Hulscher and col-
leagues, which is a randomized trial comparing en bloc
esophagectomy to transhiatal esophagectomy, although there
was no significant survival difference shown overall, when you
broke down patients into whether or not they were N0 versus pa-
tients who had 1 to 8 positive nodes and patients who had greater
than 8 positive nodes, there actually was a statistically significant
improvement in survival favoring the en bloc group for the group
of patients who had 1 to 8 positive nodes. In your analysis, were
you able to find any subpopulations of patients who seemed to de-
rive the most benefit from the enbloc approach and, if so, are thereThe Journal of Thoracic and Carany preoperative indicators that predict which patients might ben-
efit from a more extensive node dissection?
Dr Lee. Dr Altorki had published in 2001 in the Annals of Sur-
gery that looked at the number of positive lymph nodes and the pa-
tients who hadmore than 7 positive lymph nodes, again, under pN3
in the new staging system, those patients who had undergone en
bloc esophagectomy did a lot worse. So it seems if the patient
has anywhere from 1 to 6 positive lymph nodes, that patient prob-
ably gleans the most benefit from en bloc resection. But, as you
know, it is very difficult, even with endoscopic ultrasound and
PET scan, to tell precisely how many lymph nodes are involved,
andwe strugglewith the clinical staging under the new staging sys-
tem with that question.
Dr Rice. Lastly, I was struck by how few patients underwent
preoperative chemoradiation. Any potential benefit of induction
chemotherapy is likely due to the eradication of systemic micro-
metastases. Perhaps in the setting of en bloc esophagectomy, the
value of preoperative radiation would be negated. However, induc-
tion chemoradiation is, rightly or wrongly, a widely accepted treat-
ment regimen in North America. How do you think your results
should be interpreted by surgeons who are advocates of preopera-
tive chemoradiation?
Thank you very much.
Dr Lee. In our study, 80% of patients who had a recurrence ac-
tually recurred distantly. So it’s hard to imagine, given an en bloc
resection, to give another local therapy 4 or 5 weeks before an en
bloc esophagectomy. You are mainly just targeting less than 10%
of the patients. For the remaining 90% of the patients, you are
compromising probably the only treatment, which is chemother-
apy, to address the systemic disease issues.
Dr Rice. Thank you very much. I greatly enjoyed the presenta-
tion. Congratulations.
Dr Scott Swanson (Boston, Mass). I was interested in your lo-
cal recurrence rate. If I added it up correctly, it was 9 plus 4, or
about 13%, and in our published series in 2001 from the Brigham,
we had about a 3% local recurrence. Can you tell us a little more
about where it occurred and why you think it did?Was it less com-
mon in the en bloc patients?
Dr Lee. We define local recurrence as any recurrence within
a field dissection. So, for the patientwho has a 3-field lymphadenec-
tomy and recurs in the neck, we count that as a local recurrence. I
agree that the isolated local recurrence is 9%, and when you put
the two together, the recurrence rate is 13%, but bear in mind that
I think that the patients we are doing en bloc on are patients who
have locally advanced disease and, comparing it to conventional se-
ries, the recurrence rate is reported anywhere from30% to as high as
60% in traditional surgical series. I applaud your results in achiev-
ing a very low local recurrence rate but I think the 13% is pretty low
when we compare it with the conventional esophagectomies.
Dr Antoon Lerut (Leuven, Belgium). Thank you. These are ex-
cellent results indeed.
I would just like to indicate that there is our own experience and
also from The Netherlands that, in fact, there is a direct correlation
between complications and recurrences. I assume that the patients
who have a lesser performance status are thosewho are more likely
to have complications. So I assume that it is not so much the per-
formance status but rather the complications—linked, of course, to
a lesser performance status—that are in fact the reason for thediovascular Surgery c Volume 141, Number 5 1205
General Thoracic Surgery Lee et al
G
T
Shigher recurrence rate. Have you checked that particular issue?
And related to that question is what do you do with the patient
with a lesser performance status who is presenting with a stage
III carcinoma? Are you going to operate?
Dr Lee.When we look at our overall mortality, there is no dif-
ference between the en bloc and the non–en bloc group. It is be-
tween 3% and 4%. We have not looked at the postoperative
complications in this study but we do recognize in other series
that the en bloc group has a longer ICU stay, a higher incidence
of recurrent nerve injury, and more postoperative morbidity. But
we will be able to get our mortality down as low as 3% with our
en bloc group. In terms of postoperative complications, this study
has not addressed that.
DrMarkKrasna (Towson,Md).Excellent survival results. I have
2 quick questions. The first relates to the group that had transhiatal
esophagectomy. Can you tell us, on average, because you had
a very good listing of the lymph nodes resected, howmany lymph no-
des were you able to resect in the transhiatal esophagectomy group?
Dr Lee. When comparing the en bloc versus the non–en bloc,
the average is 34 in the en bloc and roughly 17 in the transhiatal
group. So we were able to average about 17 lymph nodes.
Dr Krasna. Seventeen for the transhiatal?
Dr Lee. In the transhiatal group. The abdominal dissection
is identical. The only difference, obviously, is the mediastinal
dissection.1206 The Journal of Thoracic and Cardiovascular SurDr Krasna. And the other question, again, to drill down to
something Dr Rice was alluding to, is the use of either neoadju-
vant or adjuvant therapy. Because the majority of your failures
were distant, I would agree that you definitely want to give these
patients chemotherapy. The question would be are you now go-
ing to change your regimen and offer all your patients neoadju-
vant chemotherapy or are you going to be offering all of your
patients adjuvant therapy and, if so, which approach would you
choose?
Dr Lee. It is our standard to offer any patients who are stage II
or greater disease induction chemotherapy. As we all know, they
can tolerate chemotherapy better in the preoperative setting rather
than in the postoperative setting.
Dr Raphael Bueno (Boston, Mass). The en bloc technique that
you are using, is it still the one in which you take the thoracic duct,
sometimes the azygos, and how is that going to be different from
the thoracotomy resection? You had a transhiatal and a thoracot-
omy cohort. How is the thoracotomy cohort different technically
from the en bloc technique?
Dr Lee.With a transthoracic non–en bloc, you leave the tho-
racic duct and then you just take the esophagus. You do not go
into the ipsilateral pleura and you do not do a third-field lymph
node dissection. So it is the McKeown, and sometimes patients
did have the Ivor Lewis, which is a standard non–en bloc
resection.gery c May 2011
